Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30798369 | 0.81 | NPC1 (0.41) | MAPTHTR2CNPC1RAB9AL3MBTL1 | |
| SCHEMBL30706270 | 0.73 | CYP2D6 (0.39) | LMNAMAPTL3MBTL1PKMCYP2C19 | |
| SCHEMBL24417749 | 0.72 | HTR2C (0.54) | HTR2CNPC1RAB9AL3MBTL1GAA | |
| SCHEMBL16841685 | 0.70 | DPP4 (0.46) | LMNACA1CA2HTR2CGAA | |
| SCHEMBL8508557 | 0.70 | ALDH1A1 (0.64) | LMNACA1CA2MAPTL3MBTL1 | |
| SCHEMBL28037338 | 0.70 | TSHR (0.39) | LMNAHTR2CNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL57630 | 0.69 | LMNA (0.62) | LMNACA1CA2MAPTL3MBTL1 | |
| SCHEMBL5136455 | 0.69 | LMNA (0.54) | LMNAMAPTL3MBTL1GAAPKM | |
| SCHEMBL9763993 | 0.69 | CA1 (0.48) | LMNACA1CA2MAPTTSHR | |
| SCHEMBL30353791 | 0.69 | CA1 (0.48) | LMNACA1CA2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028795-A1 | HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-02-08 | — | — | WO | disclosed |